Press Releases

Date Title and Summary View
Apr 07, 2015
MacroGenics to Present at the 14th Annual Needham Healthcare Conference
Rockville, MD , April 7, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Mar 16, 2015
MacroGenics Initiates Phase 1 Study of MGD010 for the Treatment of Autoimmune Disorders

-- First autoimmune DART(r) to enter the clinic -- MacroGenics to receive $3 million milestone payment from Takeda

Additional Formats
Mar 03, 2015
MacroGenics Provides Update on Corporate Progress and 2014 Financial Results
-- Four oncology molecules in clinical development, including two bi-specific DART® molecules -- Margetuximab Phase 3 SOPHIA study in metastatic breast cancer to initiate 3Q 2015 -- Cash runway extends into 2018 ROCKVILLE, Md. , March 3, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc.
Additional Formats
Mar 02, 2015
MacroGenics to Present at the Roth Capital Partners 27th Annual Growth Stock Conference
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig , M.D., Ph.D.,
Additional Formats
Feb 24, 2015
MacroGenics Announces Date of Fourth Quarter and Full Year 2014 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, March 3, 2015 , the Company will release its financial results for the fourth quarter and full year 2014. The Company's management team will host a conference call discussing the Company's financial results and recent corporate
Additional Formats
Feb 05, 2015
MacroGenics to Present at the Leerink Global Healthcare Conference
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that Scott Koenig , M.D., Ph.D.,
Additional Formats
Jan 27, 2015
MacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of the global collaboration and license agreement for
Additional Formats
Jan 12, 2015
MacroGenics to Present at the 33rd Annual J.P. Morgan Healthcare Conference
MacroGenics , Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases, today announced that Scott Koenig ,
Additional Formats
Dec 22, 2014
MacroGenics Enters Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies
MacroGenics licenses MGD011 (CD19 x CD3 DART®) to Janssen $50 million upfront license fee paid to MacroGenics , and a $75 million equity investment by Johnson & Johnson Innovation - JJDC, Inc. MacroGenics may elect to fund a portion of late-stage development costs in exchange for a U.S.
Additional Formats
Dec 06, 2014
MacroGenics Announces Presentation of Pre-clinical Data on new DART(r) Candidate MGD011 at 56th Annual Meeting of the American Society of Hematology

Results Support Initiation of Clinical Development of MGD011 in Hematological Malignancies

Additional Formats
Dec 03, 2014
MacroGenics to Present at the Oppenheimer 25th Annual Healthcare Conference
ROCKVILLE, Md. , Dec. 3, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Nov 12, 2014
MacroGenics to Present at the Stifel 2014 Healthcare Conference
ROCKVILLE, Md., Nov. 12, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious
Additional Formats
Nov 11, 2014
MacroGenics Provides Update on Corporate Progress and Third Quarter 2014 Financial Results
-- Four oncology molecules in clinical development; on track to have six by 2015 year-end -- Margetuximab Phase 3 study in metastatic breast cancer to initiate in 2015 -- MGD007 (gpA33 x CD3 DART) first patients dosed in colorectal cancer -- MGD011 (CD19 x CD3 DART) introduced ROCKVILLE, Md. , Nov.
Additional Formats
Nov 06, 2014
MacroGenics Announces Pre-clinical Data to be Presented at ASH 2014 Annual Meeting

New DART<font size="-1"><sup>&reg;</sup></font> Candidate: MGD011 Pre-clinical Data will be Highlighted

Additional Formats
Oct 30, 2014
MacroGenics to Present Pre-Clinical Data on MGD006 at 26th EORTC-NCI-AACR Symposium
  MacroGenics to Present Pre-Clinical Data on MGD006 at 26 th EORTC-NCI-AACR Symposium ROCKVILLE, Md. , October 30, 2014 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the
Additional Formats
Oct 28, 2014
MacroGenics Announces Date of Third Quarter 2014 Financial Results Conference Call
ROCKVILLE, Md. , October 28, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, November 11, 2014 , the Company will release its financial results for the quarter ended September 30, 2014 . The Company's management team will host a conference call discussing
Additional Formats
Sep 29, 2014
MacroGenics and Takeda Enter Second Strategic Alliance to Develop Multiple Additional DART Therapeutics
ROCKVILLE, Maryland and OSAKA, Japan , Sept. 29, 2014 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX) and Takeda Pharmaceutical Company Limited jointly announced today that they have entered into a collaboration agreement to develop and commercialize up to four product candidates.
Additional Formats
Aug 06, 2014
MacroGenics to Present at the Wedbush 2014 Life Sciences Management Access Conference
ROCKVILLE, Md. , Aug. 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Scott
Additional Formats
Aug 05, 2014
MacroGenics Provides Update on Corporate Progress and Second Quarter 2014 Financial Results

First DART(R) Molecule in Human Clinical Trial and Second DART Molecule Expected to Enter Clinic by End of Year

Additional Formats
Jul 29, 2014
MacroGenics Announces Date of Second Quarter 2014 Financial Results Conference Call
ROCKVILLE, Md. , July 29, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, August 5, 2014 , the Company will release its financial results for the quarter ended June 30, 2014 . The Company's management team will host a conference call discussing the
Additional Formats
Jul 24, 2014
MacroGenics' DART Candidate IND for Colorectal Cancer, MGD007, Cleared to Start Enrolling Patients

Triggers $5M Milestone Payment From Servier

Additional Formats
Jun 19, 2014
MacroGenics Initiates Phase 1 Study of MGD006 for the Treatment of Acute Myeloid Leukemia

MGD006 Represents the First DART(R) Molecule to Enter the Clinic

Additional Formats
May 27, 2014
MacroGenics and Takeda Enter Strategic Alliance to Develop DART for Treatment of Autoimmune Disorders
Option-based collaboration around MGD010 product candidate Incorporates MacroGenics' proprietary DART technology for bi-specific targeting of CD32B and CD79B MacroGenics has option to co-promote in the United States MacroGenics may participate in funding late-stage development in exchange for North
Additional Formats
May 07, 2014
MacroGenics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
ROCKVILLE, Md. , May 7, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Scott Koenig
Additional Formats
May 06, 2014
MacroGenics Provides Update on Corporate Progress and First Quarter 2014 Financial Results
Clinical study of first DART, MGD006, to commence in Second Quarter 2014 Phase 3 margetuximab gastroesophageal "MAGENTA" study poised for initiation in second half 2014 ROCKVILLE, Md. , May 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company
Additional Formats